Edition:
United Kingdom

Brainstorm Cell Therapeutics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

3.93USD
22 Jul 2019
Change (% chg)

$-0.06 (-1.50%)
Prev Close
$3.99
Open
$4.01
Day's High
$4.01
Day's Low
$3.90
Volume
7,841
Avg. Vol
13,363
52-wk High
$4.50
52-wk Low
$2.95

Latest Key Developments (Source: Significant Developments)

Brainstorm Cell Therapeutics Announces Successful Interim Safety Analysis In Phase 3 Trial Of Nurown Therapy For ALS
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Brainstorm Cell Therapeutics Inc ::BRAINSTORM CELL THERAPEUTICS ANNOUNCES SUCCESSFUL INTERIM SAFETY ANALYSIS IN PHASE 3 TRIAL OF NUROWN® THERAPY FOR ALS.BRAINSTORM CELL THERAPEUTICS INC - DSMB INDICATED THERE WERE NO SIGNIFICANT SAFETY CONCERNS AND RECOMMENDED THAT TRIAL CONTINUE, AS PLANNED.BRAINSTORM CELL THERAPEUTICS - ANTICIPATE COMPLETING ENROLLMENT BY MID 2019, WHICH WOULD THEN PUS US TO FILE BLA FOR US FDA APPROVAL.BRAINSTORM CELL THERAPEUTICS-DSMB COMPLETED PRE-SPECIFIED INTERIM ANALYSIS OF SAFETY OUTCOMES FOR PARTICIPANTS TREATED WITH NUROWN IN ALS PHASE 3 TRIAL.  Full Article

Brainstorm Cell Therapeutics Posts Q2 Loss Per Share $0.16
Monday, 23 Jul 2018 

July 23 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018 AND PROVIDES A CORPORATE UPDATE.Q2 LOSS PER SHARE $0.16.  Full Article

Brainstorm Cell Therapuetics Files Prospectus Relates To Resale By Selling Securityholders Of Up To 2.46 Mln Shares Of Co's Common Stock
Friday, 29 Jun 2018 

June 29 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM CELL THERAPUETICS FILES PROSPECTUS RELATES TO RESALE BY SELLING SECURITYHOLDERS OF UP TO 2.46 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY.BRAINSTORM CELL THERAPUETICS INC - APPROVAL ADVANCES CO'S APPLICATION TO ISRAEL MOH FOR TREATMENT OF ALS PATIENTS IN ISRAEL FOR A FEE.  Full Article

Brainstorm Cell Therapuetics names Eyal Rubin CFO
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer.Eyal Rubin joins co from Teva Pharmaceutical Industries Ltd.  Full Article

Brainstorm reports Q3 loss per share of $0.13
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm announces third quarter 2017 financial results.Q3 loss per share $0.13.  Full Article